By Jen Wieczner
November 23, 2015

The staff of Fortune recently assembled its predictions for 2016. Here’s one of our forecasts.

Pharma and biotech stocks swooned recently (the S&P Pharmaceuticals Select Industry Index is down 25% in the last three months), largely on concerns about greater drug price regulation. As the stocks fell, experts also observed that the sector’s frenzied M&A wave took a breather. After all, the currency fueling much of the deal-making—those companies’ inflated equity valuations—is now depressed, and acquisition targets may prefer to hold out for a higher price. While the Pfizer-Allergan merger would push the 2015 healthcare M&A total to new heights, it may also be this cycle’s last hurrah. Expect a slowdown in pharma deals in 2016.

This article is part of the 2016 Fortune Crystal Ball, a package of 33 predictions about business, politics and the economy by the writers and editors of Fortune. To see the entire package, click here.

SPONSORED FINANCIAL CONTENT

You May Like

EDIT POST